An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis
Summary
The purpose of this study is to compare the treatment effects of rabeprazole and lansoprazole depending on the genotyping (process of determining the genetic constitution) of CYP2C19 in treating reflux esophagitis (caused by gastroesophageal reflux; deterioration of the protective lining on the inner wall of the lower esophagus); and to evaluate the cure rate of reflux esophagitis on endoscopy (a thin flexible tube with a microscopic camera at the end which is passed down your throat into the esophagus, stomach, and duodenum) after treatment with rabeprazole and lansoprazole.
Timeline
- Start
- 2007-05
- Primary completion
- 2008-08
- Completion
- 2008-08
Outcome
Missed primary endpoint
registry analysis (superiority or other test); Rabeprazole vs Lansoprazole; p = 0.8849; Chi-squared; note: Homozygous extensive metabolizer NCT01008696 ↗
registry analysis (superiority or other test); Rabeprazole vs Lansoprazole; p = 0.8650; Chi-squared; note: Heterozygous extensive metabolizer NCT01008696 ↗
registry analysis (superiority or other test); Rabeprazole vs Lansoprazole; p = 0.2660; Chi-squared; note: Poor metabolizer NCT01008696 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lansoprazole | Other / unclassified | 30 mg | Oral |
| Subject | Rabeprazole | Small molecule | 20 mg | Oral |